Used primarily in the treatment of pruritus (severe itching) associated with atopic dermatitis. Targets and blocks the interleukin-31 receptor A (IL-31Ra), a key mediator in itch signaling, thereby reducing chronic itch and improving skin lesions. Also investigated for use in other pruritic conditions such as prurigo nodularis and chronic kidney disease-associated pruritus. Administered via subcutaneous injection, it offers long-term relief and improved quality of life in affected patients.